At a time when medical research is feeling the financial pinch, Congress should consider a new funding model for coordinated research into aging across both the NIH and other federal health and research agencies. Such an approach would avoid a tap on existing funds as well as the “disease-versus-disease” battle that plagues NIH appropriations year after year. Disease-specific research will always remain important, but this approach would augment collaboration and help lift all boats.
One of the most effective strategies in “bending the cost curve” in health care is preventing age-related chronic diseases in the first place. An October 2013 study published in Health Affairs hypothesizes that it will be possible by 2030 to develop interventions that increase human life expectancy at age 51 by 2.2 years—and that most of those added years would be spent in good health. These researchers also estimate that the increase in healthy years of life would have an economic benefit of approximately $7.1 trillion by the middle of this century.
In this latest edition of the Healthspan Expert Q & A, we speak with Dr. Gerard Karsenty, the Paul A. Marks M.D., professor and chair of the department of Genetics and Development at Columbia University Medical Center about his research … Continue reading →